SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

Axel S. Merseburger; Andrea B. Apolo; Simon Chowdhury; Noah M. Hahn; Matthew D. Galsky; Matthew I. Milowsky; Daniel Petrylak; Tom Powles; David I. Quinn; Jonathan E. Rosenberg; Arlene Siefker-Radtke; Guru Sonpavde; Cora N. Sternberg

doi:10.1007/s00345-018-2486-1

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

Axel S. Merseburger, Andrea B. Apolo, Simon Chowdhury, Noah M. Hahn, Matthew D. Galsky, Matthew I. Milowsky, Daniel Petrylak, Tom Powles, David I. Quinn, Jonathan E. Rosenberg, Arlene Siefker-Radtke, Guru Sonpavde, Cora N. Sternberg^*

^*Corresponding author for this work

Department of Urology

25 Citations (Scopus)

Abstract

The SIU (Société Internationale d’Urologie)–ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.

Original language	English
Journal	World Journal of Urology
Volume	37
Issue number	1
Pages (from-to)	95-105
Number of pages	11
ISSN	0724-4983
DOIs	https://doi.org/10.1007/s00345-018-2486-1
Publication status	Published - 23.01.2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

DFG Research Classification Scheme

2.22-23 Reproductive Medicine, Urology

Access to Document

10.1007/s00345-018-2486-1

Cite this

Merseburger, A. S., Apolo, A. B., Chowdhury, S., Hahn, N. M., Galsky, M. D., Milowsky, M. I., Petrylak, D., Powles, T., Quinn, D. I., Rosenberg, J. E., Siefker-Radtke, A., Sonpavde, G., & Sternberg, C. N. (2019). SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. World Journal of Urology, 37(1), 95-105. https://doi.org/10.1007/s00345-018-2486-1

@article{995b655b3bfb4d08b922cdfdf5397677,

title = "SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer",

abstract = "The SIU (Soci{\'e}t{\'e} Internationale d{\textquoteright}Urologie)–ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.",

author = "Merseburger, \{Axel S.\} and Apolo, \{Andrea B.\} and Simon Chowdhury and Hahn, \{Noah M.\} and Galsky, \{Matthew D.\} and Milowsky, \{Matthew I.\} and Daniel Petrylak and Tom Powles and Quinn, \{David I.\} and Rosenberg, \{Jonathan E.\} and Arlene Siefker-Radtke and Guru Sonpavde and Sternberg, \{Cora N.\}",

year = "2019",

month = jan,

day = "23",

doi = "10.1007/s00345-018-2486-1",

language = "English",

volume = "37",

pages = "95--105",

journal = "World Journal of Urology",

issn = "0724-4983",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

Merseburger, AS, Apolo, AB, Chowdhury, S, Hahn, NM, Galsky, MD, Milowsky, MI, Petrylak, D, Powles, T, Quinn, DI, Rosenberg, JE, Siefker-Radtke, A, Sonpavde, G & Sternberg, CN 2019, 'SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer', World Journal of Urology, vol. 37, no. 1, pp. 95-105. https://doi.org/10.1007/s00345-018-2486-1

TY - JOUR

T1 - SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

AU - Merseburger, Axel S.

AU - Apolo, Andrea B.

AU - Chowdhury, Simon

AU - Hahn, Noah M.

AU - Galsky, Matthew D.

AU - Milowsky, Matthew I.

AU - Petrylak, Daniel

AU - Powles, Tom

AU - Quinn, David I.

AU - Rosenberg, Jonathan E.

AU - Siefker-Radtke, Arlene

AU - Sonpavde, Guru

AU - Sternberg, Cora N.

PY - 2019/1/23

Y1 - 2019/1/23

N2 - The SIU (Société Internationale d’Urologie)–ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.

AB - The SIU (Société Internationale d’Urologie)–ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.

UR - https://www.scopus.com/pages/publications/85053830234

U2 - 10.1007/s00345-018-2486-1

DO - 10.1007/s00345-018-2486-1

M3 - Journal articles

C2 - 30238401

AN - SCOPUS:85053830234

SN - 0724-4983

VL - 37

SP - 95

EP - 105

JO - World Journal of Urology

JF - World Journal of Urology

IS - 1

ER -

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

Abstract

UN SDGs

DFG Research Classification Scheme

Access to Document

Other files and links

Fingerprint

Cite this